Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 1999

View Archived Issues

La Jolla presents positive results from animal studies of xenotransplantation drug

Corvas and Schering-Plough extend oral anticoagulant collaboration

Relenza now available in Canada for treament of influenza

PathoGenesis's TOBI approved in the U.K.

Emisphere Technologies to begin phase III oral heparin program

AEterna and the NCI file IND for Neovastat in North America

Excellent hypoglycemic and hypolipidemic effects reported for new Takeda compounds

Hydroxamic acids selective for TNF-alpha-processing MMPs claimed by DuPont

Dual NK1/NK2 antagonists from HMR useful for asthma and related disorders

SB presents newest research in the area of dopaminergic agents

First disease-modifying treatment for AD enters clinical testing

Antiviral compounds useful against picornaviruses and hepatitis viruses synthesized at Lilly

Novel, broad-spectrum, non-neurotoxic antiepileptic agent designed at Asta Medica

Schwarz to develop Cephalon's prostate cancer drugs in Europe

Merck KGaA terminates 70-year-old joint venture in Italy

Pediatric data support efficacy, safety of adjunctive rufinamide

Alpha7 nicotinic agonist improves working memory in preclinical model

Preclinical results indicate efficacy for NPS-1776 in various seizure types in humans

Alza and Abbott unable to complete proposed merger

Targeted Genetics commences phase I trial of tgDCC-E1A for ovarian cancer

Vertex/Glaxo Wellcome amprenavir prodrug receives fast track status

Algos discusses NDA for MorphiDex with FDA

Seretide MDI submitted for European marketing approval

Harkoseride effectively controls status epilepticus, has favorable profile for clinical development

BMS and Oxigene establish agreement for combretastatin antitumor agents

Cellegy to conduct second phase III trial with Anogesic

AVI BioPharma's restenosis antisense compound enters phase I trials

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...